Oryzon Genomics S.A.
Symbool: 0RDB.L
LSE
1.97
EURMarktprijs vandaag
-34.0078
Koers/Winst Verhouding
-1.5775
Koers/Winst Groei Verhouding
123.58M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Oryzon Genomics S.A. (0RDB-L) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 22.8 | 32.7 | 48.4 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0.1 | 0.4 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 4.1 | 4.3 | 3 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 26.9 | 37.1 | 51.8 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.7 | 0.8 | 0.8 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0.6 | 0.7 | 0.3 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.6 | 0.7 | 0.3 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 82.9 | 70 | 62.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 84.1 | 71.5 | 63.2 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 111 | 108.6 | 115 | |||||||||||
balance-sheet.row.account-payables | 0 | 5.4 | 3.3 | 2.4 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 13 | 4.7 | 5.9 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 11.1 | 15.2 | 10.6 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 1.6 | 1.8 | 1 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 13.3 | 17.6 | 12.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.1 | 0 | 0 | |||||||||||
balance-sheet.row.total-liab | 0 | 33.3 | 27.5 | 22.2 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 3 | 3 | 3.2 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -13.1 | -9.2 | -4.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 3.2 | 3.8 | 4.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 84.7 | 83.4 | 89.5 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 77.7 | 81.1 | 92.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 111 | 108.6 | 115 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | 77.7 | 81.1 | 92.8 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-debt | 0 | 24.1 | 19.9 | 16.5 | |||||||||||
balance-sheet.row.net-debt | 0 | 1.3 | -12.8 | -31.8 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -3.7 | -4.5 | -5.3 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0.2 | 0.2 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | 0.4 | 1.1 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0.3 | -0.1 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0.1 | 0.2 | ||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0.9 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | 3.7 | 2 | 0 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.1 | -0.2 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -15.2 | -13.1 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -15.3 | -13.3 | ||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.7 | -4.7 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -1.1 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 9.7 | 4.1 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 9.3 | 4.7 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0.4 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | -9.9 | -15.7 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 22.8 | 22.8 | 32.7 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 22.8 | 32.7 | 48.4 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | -2 | -4.1 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.1 | -0.2 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | -2.1 | -4.3 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 16.8 | 12.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0.5 | 0.8 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 16.3 | 11.2 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 5 | 22.1 | 18.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 5 | 22.6 | 19.7 | ||||||||||||
income-statement-row.row.interest-income | 0 | 1.3 | 0 | 0 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -1.1 | -0.4 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 17.2 | -1.1 | -0.2 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 17.2 | -1.1 | -0.2 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -1.1 | -0.4 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0.2 | 0.2 | 0.2 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | -20.9 | -5.9 | -8 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | -3.7 | -7 | -8.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 2.5 | 2.8 | ||||||||||||
income-statement-row.row.net-income | 0 | -3.7 | -4.5 | -5.3 |
Vaak gestelde vragen
Wat is Oryzon Genomics S.A. (0RDB.L) totale activa?
Oryzon Genomics S.A. (0RDB.L) totale activa is 111039575.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.983.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.447.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -1.500.
Wat is Oryzon Genomics S.A. (0RDB.L) nettowinst (netto-inkomen)?
De nettowinst is -3705000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 24113573.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 5027000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.